Zynex Inc Stock Price, News & Analysis

Zynex (NASDAQ: ZYXI), a medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring, has announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025.

Dyson brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. His extensive background includes significant board and transaction experience with various healthcare and medtech companies worldwide, including KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm.

Thomas Sandgaard, Zynex's Founder and current Chairman, will step back from day-to-day operations but remain actively involved as Chairman and Chair of the Board's Technology Committee. Dyson will operate from the company's headquarters in Englewood, Colorado, while maintaining a residence in London, England.

Zynex (NASDAQ: ZYXI) has secured UK patent 2617515 for a novel multiparameter, noninvasive sepsis monitoring device. The technology aims to address a critical global health crisis, as sepsis affects 1.7 million people annually in the US alone and causes 11 million deaths globally, with one-third of hospital deaths being sepsis-related.

The device will continuously monitor physiological signals to provide early alerts about patient sepsis status, leveraging Zynex's cardiac monitoring expertise. Early detection is crucial for patient recovery, as highlighted by the Surviving Sepsis Campaign. The technology could significantly impact treatment outcomes, particularly considering that over 50% of sepsis cases are hospital-acquired and current detection methods face timing challenges.

Zynex reported challenging Q1 2025 financial results, with net revenue declining to $26.6 million from $46.5 million year-over-year. The medical technology company faced a temporary payment suspension from its largest insurance customer, Tricare, with an appeals response expected in June.

Key financial metrics include:

• Gross profit: $18.2 million (69% of revenue), down from $37.2 million (80%)
• Net loss: ($10.4 million) or ($0.33) per share
• Cash position: $23.9 million with working capital of $40.1 million

The company implemented cost-reduction measures, including a 15% staff reduction, targeting annual savings of $35 million. Despite challenges, Zynex maintains optimism about growth opportunities in pain management and patient monitoring, with plans to submit their NiCO laser pulse oximeter for FDA approval. Q2 2025 guidance projects revenue of at least $27 million with an expected loss per share of ($0.20) or better.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its first quarter 2025 earnings conference call for Tuesday, April 29, 2025 at 4:15 PM Eastern Time.

The company will release its financial results for Q1 2025 (ended March 31, 2025) prior to the call. Management will host the conference call followed by a Q&A session. Participants can join via U.S. & Canada dial-in (800-836-8184), international number (646-357-8785), or through the webcast link available on the company's investor relations website.

Zynex (NASDAQ: ZYXI) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year 2024 highlights include a 4% revenue increase to $192.4 million, net income of $3.0 million (EPS $0.09), and operating cash flow of $12.7 million.

However, Q4 2024 showed challenges with revenue declining to $46.0 million from $47.3 million year-over-year, resulting in a net loss of ($0.6) million. A significant development is Tricare's temporary payment suspension, affecting 20-25% of annual revenue. In response, Zynex is implementing a 15% staff reduction and other cost-cutting measures, expected to save approximately $35 million annually.

The company received FDA clearance for its new TensWave device and completed positive clinical trials for the NiCO laser pulse oximeter at Duke University. For Q1 2025, Zynex projects revenue of at least $30 million with an expected loss per share of ($0.30) or better.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its Q4 and full-year 2024 earnings conference call for March 11, 2025, at 4:15 PM Eastern Time.

The company will release its financial results before the call, which will include a management presentation followed by a Q&A session. Participants can join via phone using U.S. & Canada dial-in (800-836-8184) or international number (646-357-8785), or through the webcast link available on the company's investor relations website.

Zynex (NASDAQ: ZYXI) has announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration gives Zynex access to the VA's extensive healthcare network, which spends over $112 billion annually on healthcare and serves over 9 million enrolled veterans.

The partnership encompasses 171 VAMCs and over 1,100 outpatient facilities, plus approximately 700 Military Treatment Facilities operated by the Department of Defense. Currently, less than 1% of Zynex's sales come from VAMCs, presenting a significant growth opportunity for the company's non-opioid pain management solutions.

Zynex (NASDAQ: ZYXI) has completed its clinical verification trial for the NiCO™ pulse oximeter at Duke University, marking a important milestone before FDA 510(k) submission. The device uses innovative laser technology to directly measure blood oxygenation levels, unlike traditional LED pulse oximeters that only provide estimates.

The NiCO technology aims to address accuracy issues present in current LED pulse oximeters, particularly for individuals with darker skin pigmentation. This development represents Zynex's strategic entry into the multi-billion dollar pulse oximetry market. The company will now proceed with final safety testing before submitting for FDA clearance.

Zynex (NASDAQ: ZYXI) has joined the Open Oximetry Project's Collaborative Community as an industry member. The project, led by UC San Francisco's Center for Health Equity in Surgery and Anesthesia, aims to improve pulse oximeter safety and accuracy across all populations. Zynex Monitoring Solutions is developing the NiCO™ pulse oximeter, which uses laser technology instead of traditional LED technology for more accurate blood oxygenation measurement, particularly addressing known inaccuracies in measuring oxygen levels in individuals with darker skin pigmentation. The company is in final verification studies before FDA 510(k) submission, targeting entry into the multi-billion dollar pulse oximetry market.